<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of disease-modifying therapies for multiple sclerosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of disease-modifying therapies for multiple sclerosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of disease-modifying therapies for multiple sclerosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Olek, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen Mowry, MD, MCR</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1124735147"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system that is a leading cause of disability in young adults. The disease-modifying therapies (DMTs) for MS are reviewed here.</p><p class="headingAnchor" id="H2712368557"><span class="h1">CHOOSING THERAPY</span><span class="headingEndMark"> — </span>The treatment strategy and choice of disease-modifying therapy (DMT) for MS are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129095.html" rel="external">"Indications for switching or stopping disease-modifying therapy for multiple sclerosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128298.html" rel="external">"Treatment of primary progressive multiple sclerosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">"Multiple sclerosis: Pregnancy planning"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/138599.html" rel="external">"Multiple sclerosis: Pregnancy and postpartum care"</a>.)</p><p></p><p>The treatment of acute MS exacerbations is also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1698.html" rel="external">"Treatment of acute exacerbations of multiple sclerosis in adults"</a>.)</p><p>Note that clinical trials of DMTs in MS have been performed in many populations, but mainly involving individuals of White European ancestry. In some countries, areas, and situations, this ethnicity may not reflect the composition of the population being treated. Treatment decisions should therefore be individualized.</p><p class="headingAnchor" id="H3809415602"><span class="h1">MONOCLONAL ANTIBODIES</span><span class="headingEndMark"> — </span>Monoclonal antibodies for MS include <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>, <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, and <a class="drug drug_general" data-topicid="140396" href="/z/d/drug information/140396.html" rel="external">ublituximab</a>. These disease-modifying therapies (DMTs) may be preferred for patients with more active disease and for those who place a high value on efficacy and are risk-tolerant  (<a class="graphic graphic_algorithm graphicRef102519" href="/z/d/graphic/102519.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a>.)</p><p>However, serious safety issues, including infections, are possible adverse effects of several of these medications. The indications, efficacy, dose, administration, monitoring, and adverse effects of the monoclonal antibody DMTs for MS are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">"Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis"</a>.)</p><p class="headingAnchor" id="H2452967782"><span class="h1">ORAL AGENTS</span><span class="headingEndMark"> — </span>Approved oral disease-modifying therapies (DMTs) for MS include fumarates (<a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a>, <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a>), sphingosine 1-phosphate receptor (S1PR) modulators (<a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>, <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a>), a pyrimidine synthesis inhibitor (<a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a>), and an antimetabolite purine nucleoside analog (<a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>).</p><p>Oral DMTs may be preferred for patients who value a self-administered oral medication over medications requiring injections and infusions or who largely prefer an escalation approach to therapy  (<a class="graphic graphic_algorithm graphicRef102519" href="/z/d/graphic/102519.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a>.)</p><p>These medications are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/143125.html" rel="external">"Clinical use of oral disease-modifying therapies for multiple sclerosis"</a>.)</p><p class="headingAnchor" id="H1608153633"><span class="h1">INJECTION THERAPIES</span></p><p class="headingAnchor" id="H1406802795"><span class="h2">Platform therapies</span><span class="headingEndMark"> — </span>Injectable (intramuscular and subcutaneous) forms of disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) include the interferon beta (IFNB) preparations and <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a>. The interferons and glatiramer acetate were the earliest DMTs for RRMS, with the first approved in 1993; they are sometimes called the "platform" therapies for this reason. The available evidence from controlled trials suggests that interferons and glatiramer acetate have similar clinical utility [<a href="#rid1">1</a>].</p><p>These older DMTs may be preferred for patients who value safety and are less concerned about convenience or who are comfortable utilizing an escalation approach to treatment  (<a class="graphic graphic_algorithm graphicRef102519" href="/z/d/graphic/102519.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a>.)</p><p class="headingAnchor" id="H1471873820"><span class="h3">Interferons</span><span class="headingEndMark"> — </span>Interferons are cytokines that modulate immune responsiveness through various mechanisms [<a href="#rid2">2-4</a>]. Several interferon IFNB preparations are effective for the treatment of RRMS, as presented below.</p><p class="headingAnchor" id="H3836322301"><span class="h4">Indications</span><span class="headingEndMark"> — </span>IFNBs are indicated for the treatment of relapsing forms of MS, including clinically isolated syndrome (CIS), RRMS, and active secondary progressive multiple sclerosis (SPMS). IFNBs are contraindicated for patients with a history of hypersensitivity to IFNB or other components of the formulations.</p><p class="headingAnchor" id="H3349042790"><span class="h4">Dose and administration</span><span class="headingEndMark"> — </span>Dosing of the different interferon beta drugs differs according to the formulation and route of administration. Coadministration of analgesics and/or antipyretics on treatment days may help to minimize flu-like symptoms [<a href="#rid5">5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interferon beta-1b </strong>– <a class="drug drug_general" data-topicid="8566" href="/z/d/drug information/8566.html" rel="external">Recombinant human interferon beta-1b</a> is administered at 0.25 mg (1 mL) every other day subcutaneously by self-injection [<a href="#rid6">6</a>]. Generally, the drug is started at 0.0625 mg (0.25 mL) every other day and increased over a six-week period to 0.25 mg (1 mL) every other day. One dose titration schedule begins at 0.0625 mg (0.25 mL) every other day for the first two weeks of therapy and is increased to 0.125 mg (0.5 mL) every other day for weeks 3 and 4, to 0.185 mg (0.75 mL) every other day for weeks 5 and 6, and to the final dose of 0.25 mg (1 mL) every other day beginning at week 7 and thereafter [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intramuscular interferon beta-1a </strong>– Intramuscular <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a> is dosed at 30 mcg once weekly. To minimize flu-like symptoms, one strategy is to start with 7.5 mcg (week 1) then increase dose in increments of 7.5 mcg once weekly (during weeks 2, 3, and 4) up to the recommended dose (30 mcg once weekly) [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subcutaneous interferon beta-1a</strong> – Subcutaneous <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a> is given as a dose of 22 mcg three times weekly or 44 mcg three times weekly [<a href="#rid8">8</a>]. The lower dose is generally used for patients who do not tolerate the higher dose. Dose titration schedules for each target dose follow:</p><p></p><p class="bulletIndent1">Target dose 44 mcg three times weekly:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial dose 8 mcg three times weekly for weeks 1 and 2</p><p class="bulletIndent2"><span class="glyph">•</span>Increase to 22 mcg three times weekly for weeks 3 and 4</p><p class="bulletIndent2"><span class="glyph">•</span>Increase to 44 mcg three times weekly for week 5 and thereafter</p><p></p><p class="bulletIndent1">Target dose 22 mcg three times weekly:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial dose 4.4 mcg three times weekly for weeks 1 and 2</p><p class="bulletIndent2"><span class="glyph">•</span>Increase to 11 mcg three times weekly for weeks 3 and 4</p><p class="bulletIndent2"><span class="glyph">•</span>Increase to 22 mcg three times weekly for week 5 and thereafter</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pegylated interferon beta-1a</strong><strong> </strong>– Pegylated <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a> is given by subcutaneous or intramuscular injection. The recommended target dose is 125 mcg every 14 days. The dose is titrated, beginning with 63 mcg on day 1, 94 mcg on day 15, and 125 mcg (the full dose) on day 29 [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H2474790609"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span>Injection site reactions are common with IFNB therapy and may include injection site abscess, cellulitis, or necrosis [<a href="#rid5">5-8</a>]. Flu-like symptoms are also common and may be treated with <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, and glucocorticoids [<a href="#rid9">9</a>]. The routine use of acetaminophen should probably be avoided as it may increase the risk of liver dysfunction associated with IFNB use. Flu-like symptoms tend to diminish with time. However, for some patients they remain intolerable. Although depression has been reported as a possible adverse effect of IFNB therapy, the association has not been confirmed [<a href="#rid10">10-12</a>], and a 2010 meta-analysis of placebo-controlled randomized trials on the efficacy and/or tolerability of IFNB in MS found no increase in depression with IFNB therapy [<a href="#rid13">13</a>].</p><p>There is a relatively high prevalence of mainly asymptomatic liver dysfunction (transaminitis) associated with IFNB therapy [<a href="#rid14">14,15</a>]. However, serious hepatotoxicity associated with IFNB is rare. Nevertheless, the potential risk of using IFNB in combination with known hepatotoxic drugs or other products (eg, alcohol) should be considered prior to IFNB administration, or when adding new agents to the regimen of patients already on an IFNB.</p><p>Rare but potentially life-threatening cases of pulmonary artery hypertension have been reported with IFNB [<a href="#rid16">16,17</a>], as have rare cases of thrombotic microangiopathy [<a href="#rid18">18-20</a>]. The relationship with thrombotic microangiopathy appears to be dose-dependent, suggesting a toxicity mechanism [<a href="#rid20">20</a>]. IFNB treatment should be stopped immediately for patients who develop pulmonary artery hypertension or thrombotic microangiopathy. (See  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a> and  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Immunosuppressive agents'</a>.)</p><p>Other adverse reactions possibly related to IFNB therapy include leukopenia and anemia, anaphylaxis and other allergic reactions, congestive heart failure, seizures, and drug-induced lupus erythematosus. A partially reversible polyneuropathy was described in a small series of patients with MS who were treated with IFNB therapy [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H1927601253"><span class="h4">Monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory abnormalities</strong> – Periodic monitoring is recommended to include complete blood count and differential, platelet count, blood chemistries, and liver function tests at one, three, and six months following the start of IFNB therapy, and periodically thereafter; thyroid function testing is also suggested for patients on IFNB therapy [<a href="#rid5">5-8</a>]. However, the optimal frequency of monitoring has not been established; it is unclear whether monitoring these laboratory studies is helpful for detecting and avoiding the rare cases of serious IFNB-related toxicity.</p><p></p><p class="bulletIndent1">We suggest checking liver function tests monthly for six months after initiating therapy (or months 1, 2, 3, and 6), and thereafter repeat the liver function tests and complete blood count every six months.</p><p></p><p class="bulletIndent1">In the past, we suggested decreasing the IFNB dose by 50 percent if leukopenia develops or if transaminases are persistently elevated (eg, illness, a new medication, or alcohol intake); monitoring should then be continued for another six months. However, a dose reduction of this magnitude may lower the effectiveness of IFNB therapy; with the availability of many other options, this possibility should prompt a discussion with the patient about switching to another DMT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutralizing antibodies and response markers</strong> – The development of neutralizing antibodies (NAbs) may limit the effectiveness of interferons as measured by magnetic resonance imaging (MRI) activity, relapses, and disease progression [<a href="#rid22">22-26</a>]. All of the interferons are capable of stimulating the production of NAbs, which reduce the bioavailability of interferon [<a href="#rid27">27</a>]. The rate of NAb formation varies with the type of interferon, the dosing regimen, and duration of IFNB therapy [<a href="#rid28">28</a>]. In one study, 34 percent of patients taking interferon beta-1b developed NAbs [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">In our view, trials establishing the utility of NAb or myxovirus resistance protein A (MxA) testing for patients receiving IFNB therapy are needed before the routine use of these markers can be recommended. However, the negative impact of NAbs on relapses and disease progression led some experts to call for NAb testing in clinical practice [<a href="#rid30">30-32</a>]. Our approach has been that, in the setting of high disease activity, therapy should be changed independent of Nab or MxA results, though neutralizing antibody testing can inform the selection of ensuing treatment. For patients who have NAb titers, a switch to a non-IFNB therapy would be indicated [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H2639442052"><span class="h4">Efficacy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interferon beta-1b</strong> – The first disease-modifying medication approved for use in MS was <a class="drug drug_general" data-topicid="8566" href="/z/d/drug information/8566.html" rel="external">recombinant human interferon beta-1b</a>.</p><p></p><p class="bulletIndent1">The efficacy of subcutaneous interferon beta-1b was demonstrated in a double-blind, placebo-controlled trial of 372 patients with RRMS who were randomly assigned to treatment with either interferon beta-1b 50 mcg every other day, interferon beta-1b 250 mcg every other day, or placebo [<a href="#rid33">33</a>]. After two years, the annual exacerbation rate was significantly lower for both interferon beta-1b treatment groups and appeared to be dose related; the frequency of relapses was 1.27/year in the placebo group, compared with 1.17/year and 0.84/year in the low- and high-dose interferon beta-1b groups, respectively [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">At five-year follow-up, the incidence of disease progression was lower in the high-dose (250 mcg) interferon beta-1b group compared with the placebo group (35 versus 46 percent) [<a href="#rid34">34</a>]. There was no significant increase in the median brain MRI lesion burden in the interferon beta-1b group, while the placebo group had a 30 percent increase in median MRI lesion burden over five years. At a median of 21-year follow-up with nearly complete ascertainment (98 percent) of patients, the rate of all-cause mortality was significantly lower for those originally assigned to low- and high-dose interferon beta-1b treatment (17.9 and 18 percent, versus 30.6 percent for those originally assigned to placebo) [<a href="#rid35">35</a>]. Patients in this extension study received the assigned treatment for up to five years, and subsequent use of DMT was optional and unmasked. Therefore, these data suggest that earlier and/or longer exposure to interferon beta-1b treatment improves survival for patients with MS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interferon beta-1a</strong> – <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">Recombinant human interferon beta-1a</a> is available in several different formulations, including intramuscular, subcutaneous, and pegylated preparations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intramuscular interferon beta-1a</strong> – A double-blind trial randomly assigned 301 patients with RRMS to intramuscular interferon beta-1a 6 million units (30 mcg) once a week or to placebo [<a href="#rid36">36</a>]. Over two years, treatment with intramuscular interferon beta-1a led to a reduction in the annual exacerbation rate compared with placebo (0.61 and 0.9, respectively), a decrease in MRI lesion volume (mean 74 versus 122), and fewer patients progressing by one point on the Expanded Disability Status Scale (EDSS) (22 versus 35 percent). In a subsequent randomized, double-blind study, a higher dose of intramuscular interferon beta-1a (60 mcg per week) was not superior to 30 mcg [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subcutaneous interferon beta-1a</strong> – The double-blind PRISMS trial randomly assigned 560 patients with RRMS to placebo, 22 mcg, or 44 mcg of subcutaneous interferon beta-1a three times per week for two years [<a href="#rid29">29</a>]. Treatment with 22 or 44 mcg was associated with a significant reduction in relapse rate (27 and 33 percent, respectively) compared with placebo. Treatment also reduced the MRI lesion burden in the low- and high-dose treatment groups (1.2 and 3.8 percent) versus an increase in the placebo group (10.9 percent).</p><p></p><p class="bulletIndent2">The EVIDENCE trial enrolled 677 patients who were randomly assigned to receive subcutaneous interferon beta-1a 44 mcg three times weekly or intramuscular interferon beta-1a 30 mcg once a week [<a href="#rid38">38</a>]. Relapse was less frequent with subcutaneous interferon beta-1a (25 versus 37 percent), and the mean number of active MRI lesions per patient per scan was fewer (0.17 versus 0.33). However, treatment with subcutaneous interferon beta-1a was associated with a substantially higher rate of developing NAbs (25 versus 2 percent). The percentage of relapse-free patients, the primary outcome measure, was lower in the group assigned to subcutaneous interferon beta-1a who developed NAbs.</p><p></p><p class="bulletIndent2">In addition to concerns regarding neutralizing antibody formation, there were several criticisms of the EVIDENCE trial: the subjects were not blind to treatment assignment, the duration was relatively short (six months), disability was not assessed as an outcome measure, and different doses, frequencies, and routes of administration were compared [<a href="#rid39">39,40</a>].</p><p></p><p class="bulletIndent2">In an extension of the EVIDENCE trial, patients who changed from low-dose intramuscular interferon beta-1a (30 mcg once weekly injection) to high-dose subcutaneous interferon beta-1a (44 mcg three times weekly injection) experienced a statistically significant (50 percent) decrease in the annualized relapse rate, while patients continuing on high-dose interferon beta-1a experienced a nonsignificant (26 percent) decrease [<a href="#rid41">41</a>]. The higher dose of interferon beta-1a was associated with an increased rate of adverse effects.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pegylated</strong> <strong>interferon beta-1a</strong><strong> </strong>– Pegylation is a process of drug modification that attaches a polyethylene glycol (PEG) group to the N terminus of interferon beta-1a [<a href="#rid42">42</a>]. Pegylation can improve some pharmacodynamic properties, including a longer half-life and consequently a reduced dosing frequency [<a href="#rid42">42,43</a>]. Peginterferon beta-1a was evaluated in the ADVANCE trial, which randomly assigned 1512 adults with RRMS in a 1:1:1 ratio to treatment with subcutaneous peginterferon 125 mcg once every two weeks, peginterferon 125 mcg once every four weeks, or placebo [<a href="#rid44">44</a>]. At 48 weeks, the annualized relapse rates for the peginterferon every-two-week group, the every-four-week group, and placebo group were 0.256, 0.288, and 0.397, respectively. The corresponding relative risk reduction for the group receiving pegylated interferon every two weeks versus the placebo group was 0.64 (95% CI 0.50-0.83), while the absolute risk reduction was 0.14. Peginterferon treatment also led to improvement on several other outcome measures, including a slight reduction in sustained disability progression and a reduction in several MRI measures of brain lesion activity. The preparation was generally well tolerated; the most common adverse events were injection-site reactions, influenza-like illness, and headache.</p><p></p><p class="bulletIndent2">These results suggest that peginterferon beta-1a is effective for the treatment of RRMS. Because it requires fewer injections, peginterferon beta-1a may be better tolerated than nonpegylated IFNB formulations. However, there are no data directly comparing pegylated with nonpegylated formulations, and longer-term studies are needed to confirm the benefit and safety of peginterferon beyond the first year.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Studies comparing interferon beta-1b with beta-1a</strong> – The INCOMIN study compared subcutaneous interferon beta-1b 0.25 mg every other day with intramuscular interferon beta-1a 30 mcg once weekly in 188 patients with RRMS and found the former to be more effective on both clinical and MRI outcomes [<a href="#rid45">45</a>]. The trial design did not include blinding, but careful randomization was performed, and clinical results were consistent with MRI results, the latter of which were obtained from a blinded analysis. Over two years, more patients receiving interferon beta-1b remained relapse-free than those assigned to interferon beta-1a (51 versus 36 percent, relative risk of relapse 0.76, 95% CI 0.59-0.9).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term benefit of interferons</strong> – The benefit of long-term treatment with IFNB preparations for RRMS remains unproven. As reviewed above, randomized controlled trials of these agents provide evidence of benefit only for the relatively short duration (generally two years) of the trials. Results from a number of clinical trial extension studies suggest that there is continued benefit of IFNB treatment beyond two years [<a href="#rid35">35,46,47</a>]. However, definitive conclusions are precluded by limitations of these studies, which involve uncontrolled open-label treatment with unblinded and retrospective assessment of clinical events and, often, large numbers of patients lost to follow-up. Long-term blinded randomized controlled trials of IFNB therapy for RRMS are ideally suited to settling this issue but are considered impractical and possibly unethical [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1">Long-term observational studies are more practical but are similarly limited by nonrandomized retrospective methodology and other issues, including potential confounding by indication and inability to assess treatment strategy or account for treatment adherence. Most of these studies too suggest that IFNB treatment for MS does not prevent long-term disability [<a href="#rid49">49-51</a>], though a minority suggests otherwise [<a href="#rid52">52</a>].</p><p></p><p class="headingAnchor" id="H2068216490"><span class="h3">Glatiramer acetate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">Glatiramer acetate</a> (copolymer 1) is a mixture of random polymers of four amino acids. The mixture is antigenically similar to myelin basic protein, a component of the myelin sheath of nerves. In experimental models, the immunomodulatory mechanism of action for glatiramer acetate involves binding to major histocompatibility complex molecules and consequent competition with various myelin antigens for their presentation to T cells [<a href="#rid53">53</a>]. In addition, glatiramer acetate is a potent inducer of specific T helper 2 type suppressor cells that migrate to the brain and lead to bystander suppression; these cells also express anti-inflammatory cytokines.</p><p class="headingAnchor" id="H2412659386"><span class="h4">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">Glatiramer acetate</a> is indicated for the treatment of relapsing forms of MS, including CIS, RRMS, and active SPMS.</p><p class="headingAnchor" id="H1539473729"><span class="h4">Dose and administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">Glatiramer acetate</a> is administered by subcutaneous injection. There are two different doses, which are <strong>not</strong> interchangeable [<a href="#rid54">54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>20 mg daily</p><p class="bulletIndent1"><strong>or</strong></p><p class="bulletIndent1"><span class="glyph">●</span>40 mg three times a week and at least 48 hours apart</p><p></p><p class="headingAnchor" id="H431328802"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span>Side effects of <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a> include local injection site reactions and, less commonly, transient systemic postinjection reactions such as chest pain, flushing, dyspnea, palpitations, tachycardia, urticaria, and/or anxiety [<a href="#rid54">54</a>]. Other potential adverse effects include lipoatrophy and skin necrosis. Desensitization to glatiramer acetate has been successfully performed in patients with either systemic allergic reactions or recurrent local reactions [<a href="#rid55">55</a>].</p><p>Serious adverse effects due to <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a> are uncommon, but cases of hepatotoxicity, some severe, have been reported [<a href="#rid56">56-58</a>].</p><p>NAbs to <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a> have been detected in some studies, but their clinical significance is unknown [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H290408948"><span class="h4">Monitoring</span><span class="headingEndMark"> — </span>No laboratory monitoring is necessary.</p><p class="headingAnchor" id="H698363911"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>A number of randomized trials have demonstrated the effectiveness of <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a> in RRMS [<a href="#rid60">60</a>]. The benefit of glatiramer acetate was first established in a double-blind trial of 251 patients with RRMS [<a href="#rid61">61</a>]. At two years, patients treated with glatiramer acetate (20 mg subcutaneously daily) had a significantly lower relapse rate than those receiving placebo (1.19 versus 1.68). Furthermore, over 140 weeks, a significantly larger proportion of patients in the placebo group experienced increased disability by ≥1.5 steps on the EDSS compared with the treatment group (41 versus 22 percent) [<a href="#rid62">62</a>]. In another trial, glatiramer acetate was given at 40 mg three times a week and led to a reduction in confirmed relapses of 34 percent compared with placebo (mean annualized relapse rate, 0.33 versus 0.51) and to a lower rate of gadolinium-enhancing lesions and new or enlarging T2 lesions on MRI [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H1201901661"><span class="h2">Ofatumumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">Ofatumumab</a>, while given by subcutaneous injection, is a monoclonal antibody that was approved in 2020 and is discussed with the other monoclonal antibodies. (See  <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">"Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis", section on 'Ofatumumab'</a>.)</p><p class="headingAnchor" id="H2888673067"><span class="h1">OTHER IMMUNE MODULATING AGENTS</span><span class="headingEndMark"> — </span>Before the approval of injection therapies (interferons and <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a>), and based on limited evidence, several immunosuppressive agents were used to treat MS, including <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, glucocorticoids, intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), and <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a>. However, these agents are less often used for MS now that disease-modifying therapies (DMTs) with proven efficacy are available [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H2973390790"><span class="h2">Azathioprine</span><span class="headingEndMark"> — </span>Early trials of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> for MS were small and conflicting [<a href="#rid65">65-67</a>]. Nevertheless, in a meta-analysis that identified five randomized controlled trials involving 698 patients with MS, azathioprine compared with placebo was associated with a statistically significant reduction in the number of patients who had MS relapses during the first, second, and third years of treatment; relative risk reductions for these periods were 20, 23, and 18 percent, respectively [<a href="#rid68">68</a>]. Approximately 55 percent of the pooled patients included in the meta-analysis had relapsing-remitting multiple sclerosis (RRMS), while the remainder had progressive forms of MS; all of the trials were published prior to 1994.</p><p>Few studies have evaluated <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> for MS in the modern MRI era. One small, open-label study found that azathioprine up to 3 mg/kg per day was well tolerated and reduced the rate of new gadolinium-enhancing brain lesions in patients with RRMS [<a href="#rid69">69</a>]. The benefit and tolerability of azathioprine for patients with RRMS requires confirmation in larger blinded, randomized trials.</p><p class="headingAnchor" id="H543793880"><span class="h2">Cyclophosphamide</span><span class="headingEndMark"> — </span>Limited observational evidence supports the use of pulse (eg, monthly) intravenous (IV) <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for RRMS [<a href="#rid70">70</a>]. There is more experience with pulse cyclophosphamide for progressive forms of MS, but data are conflicting regarding benefit. (See  <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults", section on 'Other treatments'</a>.)</p><p>Another option employs high-dose <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> as immunoablative treatment without bone marrow transplantation [<a href="#rid71">71,72</a>]. In an open-label study, nine patients with active inflammatory RRMS were treated with IV cyclophosphamide (50 mg/kg daily) for four days, followed by granulocyte colony-stimulating factor [<a href="#rid72">72</a>]. At a mean follow-up of 23 months, there was a statistically significant improvement in disability and a reduction in the mean number of gadolinium-enhancing lesions compared with pretreatment, and there were no serious adverse events. However, two patients developed MS exacerbations and required rescue treatment with other immunomodulatory drugs. Larger studies are needed to determine the effectiveness and safety of this approach, and it is not recommended for use outside of clinical trials.</p><p class="headingAnchor" id="H1090669323"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Monthly IV glucocorticoid boluses, typically 1000 mg of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, were once used at many institutions for the treatment of primary or secondary progressive MS alone or in combination with other immunomodulatory or immunosuppressive medications. However, randomized trial data are limited and inconclusive regarding any benefit of glucocorticoids in combination with interferon beta (IFNB) preparations for RRMS [<a href="#rid73">73-75</a>]. Thus, the role of glucocorticoids combined with beta interferons or other agents for the treatment of RRMS remains uncertain.</p><p class="headingAnchor" id="H1520736283"><span class="h2">Intravenous immune globulin</span><span class="headingEndMark"> — </span>Although data are equivocal, there is no compelling evidence that <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> is effective for patients with RRMS. Some [<a href="#rid76">76-79</a>] but not all [<a href="#rid80">80</a>] early clinical trials reported beneficial effects for IVIG in RRMS. However, these trials generally involved small numbers of patients, lacked complete data on clinical and MRI outcomes, or used questionable methodology [<a href="#rid81">81</a>]. A later multicenter placebo-controlled trial of 127 patients with RRMS found that IVIG treatment conferred no benefit for reducing relapses or new lesions on MRI [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H362561489"><span class="h2">Mitoxantrone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">Mitoxantrone</a> is approved for use in both relapsing-remitting and progressive forms of MS. However, because of cardiac toxicity, an increased risk of ovarian failure, male infertility, chromosomal aberrations, and promyelocytic leukemia, mitoxantrone should <strong>not</strong> be used to treat MS unless potential benefits greatly outweigh the risks [<a href="#rid83">83,84</a>]. Thus, mitoxantrone is considered only as a last resort for patients with rapidly advancing disease who have failed other therapies [<a href="#rid85">85</a>]. Due to these potential adverse effects, there is a maximum lifetime dose.</p><p>The usual dose of <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> is 12 mg/m<sup>2</sup> by IV administration every three months up to a maximum cumulative lifetime dose of 140 mg/m<sup>2</sup> [<a href="#rid86">86</a>]. The left ventricular ejection fraction (LVEF) should be evaluated before initiating mitoxantrone and prior to each subsequent dose and should be maintained at ≥50 percent. In addition, annual cardiac testing should continue after completion of mitoxantrone therapy because of concern for delayed cardiotoxicity. In patients with MS treated with mitoxantrone, a systematic review published in 2010 estimated that the risks of developing systolic dysfunction, heart failure, and acute leukemia were 12, 0.4, and 0.8 percent, respectively [<a href="#rid86">86</a>]. In patients with cancer who were treated with mitoxantrone, the rate of heart failure was estimated to be approximately 3 percent.</p><p>Patients older than age 50, those with long-standing disability, and those with substantial spinal cord atrophy may be less likely to respond to intense immunosuppression with agents such as <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a> or any DMT than patients without these characteristics [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H1152190152"><span class="h1">STEM CELL TRANSPLANTATION</span><span class="headingEndMark"> — </span>The goal of autologous hematopoietic stem cell transplantation (HSCT) is eliminating and replacing the patient's pathogenic immune system to achieve long-term remission of MS [<a href="#rid88">88</a>]. The process involves mobilizing and harvesting hematopoietic stem cells from the patient's peripheral blood or bone marrow, followed by a conditioning regimen of chemotherapy, sometimes with immune-depleting biologic agents or radiation therapy, to partially or totally ablate the patient's immune system. The last step is infusing the harvested stem cells to regenerate the immune system.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsing forms of MS</strong> – The open-label MIST trial randomly assigned 110 patients with highly active relapsing-remitting multiple sclerosis (RRMS) on disease-modifying therapy (DMT) to nonmyeloablative HSCT with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (200 mg/kg) and antithymocyte globulin (6 mg/kg) or to another DMT of higher efficacy or different class than the DMT they were taking at baseline [<a href="#rid89">89</a>]. At a median follow-up of two years, disease progression, defined as an increase of one point on the Expanded Disability Status Scale (EDSS), occurred in 5 percent in the HSCT group and 62 percent in the DMT group; median time to disease progression could not be calculated in the HSCT group due to an insufficient number of events and was 24 months in the DMT group (hazard ratio 0.07, 95% CI 0.02-0.24). Compared with the DMT group, the HSCT group had a lower relapse rate, an improvement in MRI lesion volume, and a greater proportion of patients with no evidence of disease activity at follow-up. There were no deaths and no disabling or potential life-threatening adverse events among the patients who received HSCT.</p><p></p><p class="bulletIndent1">In an open-label study (HALT-MS) of 24 patients with refractory RRMS, myeloablation with high-dose immunotherapy followed by HSCT was associated with a high rate of event-free survival at three and five years (78 and 69 percent, respectively) and improvements in neurologic function [<a href="#rid90">90,91</a>]. Adverse events included three deaths, all in patients with MS progression; none of the deaths were attributed to transplant. In another open-label study, 24 adults with refractory MS, early disability, and ongoing disease activity were treated with immunoablation followed by autologous HSCT [<a href="#rid92">92</a>]. Complications of transplantation caused one death. Among survivors, there were no relapses and no evidence of new MRI gadolinium-enhancing lesions or new T2 lesions. With a median follow-up of 6.7 years, the rate of MS clinical disease activity-free survival at three years after transplantation was 70 percent.</p><p></p><p class="bulletIndent1">These and other reports illustrate the potential benefits and perils of HSCT [<a href="#rid93">93-98</a>]. More long-term data from randomized controlled trials are needed to assess the efficacy and safety of this intervention for the treatment of highly active RRMS [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progressive forms of MS</strong> – HSCT has been evaluated in uncontrolled studies of patients with progressive forms of MS [<a href="#rid100">100-103</a>]. A 2011 systematic review of autologous HSCT in patients with progressive MS refractory to conventional medical treatment identified eight case series with 161 patients (most with secondary progressive multiple sclerosis [SPMS]) that reported progression-free survival, which ranged from 33 to 95 percent at median follow-up times of 24 to 42 months [<a href="#rid104">104</a>]. There was substantial heterogeneity among these studies, which appeared to be due mainly to the intensity of the immunoablative conditioning regimen employed prior to HSCT.</p><p></p><p class="bulletIndent1">Among 15 studies that reported adverse events, the most frequent complications occurring within six months of autologous HSCT were fever, engraftment syndrome, enteritis, and transient neurologic deterioration [<a href="#rid104">104</a>]. Among 13 case series with posttreatment follow-up, seven patients died from treatment-related causes, mainly infection, and six patients died from nontreatment-related causes, mainly disease progression. Overall mortality was approximately 3 percent. Transplant-related mortality was as high as 8 percent in older studies [<a href="#rid105">105,106</a>] but appears to be lower since the year 2000 [<a href="#rid97">97,100,104</a>].</p><p></p><p>In addition to HSCT, mesenchymal stem cell therapy for MS is being explored, with inconsistent results in small studies [<a href="#rid107">107-111</a>]. Larger controlled trials are awaited to evaluate the risk/benefit ratio of stem cell therapies and their appropriate indications for the treatment of MS.</p><p class="headingAnchor" id="H2110078159"><span class="h1">COVID-19 AND DMTs</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID vaccinations in patients with MS</strong> – We advise coronavirus disease 2019 (COVID-19) vaccination and boosters for all patients with MS, in accordance with local availability and allocation priorities [<a href="#rid112">112,113</a>]. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p></p><p class="bulletIndent1">Note that COVID-19 vaccination, and likely other vaccinations, may be less effective in patients being treated with anti-CD20 or sphingosine 1-phosphate receptor (S1PR) modulator disease-modifying therapies (DMTs) due to attenuated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response [<a href="#rid114">114,115</a>].</p><p></p><p class="bulletIndent1">For patients starting B-cell depleting DMTs, COVID vaccines should be given prior to commencing therapy when possible. In instances when COVID vaccination has to be given after therapy has been instituted, timing should be arranged for a cycle in the treatment when the immune response is likely to be maximal, which is generally as long after the most recent DMT infusion as possible but approximately two weeks prior to next expected dose (for infused anti-CD20 therapies) [<a href="#rid116">116</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DMTs that may increase the risk of severe COVID-19</strong> – There are concerns about DMTs (eg, <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>, <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>, and others) that cause B cell or lymphocyte depletion, which theoretically may increase the risk of developing severe COVID-19 [<a href="#rid117">117,118</a>].</p><p></p><p class="bulletIndent1">Observational data suggest that anti-CD20 DMTs for MS increase the risk for more severe COVID-19 illness [<a href="#rid118">118-122</a>]. As an example, a multinational cohort study that included 1683 patients with MS and confirmed COVID-19 found that the risk of hospitalization was increased for patients taking either <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a> (adjusted odds ratio [aOR] 1.75, 95% CI 1.29-2.38) or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (aOR 2.76, 95% CI 1.87-4.07) compared with those taking other DMTs [<a href="#rid121">121</a>]. Both ocrelizumab and rituximab were also associated with higher risk of intensive care unit admission, but neither was associated with an increased risk of death.</p><p></p><p class="bulletIndent1">Note that several DMTs, including <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> and <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>, are not well studied for their impact on the severity of COVID-19.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DMTs unlikely to increase the risk of more severe COVID-19</strong> – Observational evidence suggests that there is no increased risk of severe COVID-19 infection associated with DMTs for patients using <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a>, fumarates (<a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a>, <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a>), or S1PR modulators (<a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>, and <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a>), although not all of these agents have been specifically evaluated [<a href="#rid117">117,118,121,123</a>]. In addition, the platform DMTs (the interferons and <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a>) have not been associated with increased severity of COVID-19 [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individualized approach for patients at risk for severe COVID-19 </strong>– We advise an individualized approach for the use of DMTs that considers MS disease activity, lymphocyte count, and the presence of comorbid conditions, in addition to MS itself, which may increase the risk associated with COVID-19  (<a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">table 1</a>) [<a href="#rid124">124</a>]. Depending upon the degree of inflammatory MS activity, it may be reasonable to delay dosing or starting anti-CD20 DMTs (<a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>) to allow time for the patient to be fully vaccinated against COVID-19 (eg, for two to eight weeks depending upon which vaccine is used and how quickly it can be given), but there is no high-quality evidence to guide these decisions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who develop COVID-19</strong> – Clinicians should advise patients with MS who develop symptoms suggestive of COVID-19 or test positive for COVID-19 to contact their MS health care professional for advice about DMT management [<a href="#rid125">125</a>].</p><p></p><p class="bulletIndent1">For patients who develop severe COVID-19, it may be reasonable to stop monoclonal antibody DMTs (<a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> and anti-CD20 therapies) until the recovery phase of the disease [<a href="#rid117">117</a>], but evidence is limited. Another approach is to treat with <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a> for adults of any age, given the immunocompromised state associated with DMTs for MS. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Nirmatrelvir-ritonavir as preferred therapy'</a>.)</p><p></p><p class="bulletIndent1">If DMTs are stopped, some experts advise restarting treatment with <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> within eight weeks, circumstances permitting, to avoid rebound disease [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1">The management of COVID-19 is discussed in several UpToDate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/128349.html" rel="external">"COVID-19: Management in nursing homes"</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a> and  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p></p><p class="headingAnchor" id="H2928149250"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117065.html" rel="external">"Society guideline links: Multiple sclerosis and related disorders"</a>.)</p><p class="headingAnchor" id="H65541213"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monoclonal antibody DMTs</strong> – Monoclonal antibody disease-modifying therapies (DMTs) for multiple sclerosis (MS) include <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> and biosimilars, several anti-CD20 agents (<a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>, <a class="drug drug_general" data-topicid="140396" href="/z/d/drug information/140396.html" rel="external">ublituximab</a>), and <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>. These DMTs are highly efficacious and may be preferred for patients with more active disease and for those who place a high value on efficacy and are risk-tolerant  (<a class="graphic graphic_algorithm graphicRef102519" href="/z/d/graphic/102519.html" rel="external">algorithm 1</a>). However, serious safety issues, including infections, are possible adverse effects of several of these medications. The monoclonal antibody DMTs are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">"Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral DMTs for MS</strong> – Oral DMTs for MS include fumarates (<a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a>, <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a>), sphingosine 1-phosphate receptor (S1PR) modulators (<a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>, and <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a>), <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>, and <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a>. These DMTs may be preferred for patients with MS who value a self-administered oral medication over medications requiring injections and infusions  (<a class="graphic graphic_algorithm graphicRef102519" href="/z/d/graphic/102519.html" rel="external">algorithm 1</a>). They are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/143125.html" rel="external">"Clinical use of oral disease-modifying therapies for multiple sclerosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platform injection therapies</strong> – Older injectable (intramuscular and subcutaneous) DMTs include the interferon beta agents (<a class="drug drug_general" data-topicid="8566" href="/z/d/drug information/8566.html" rel="external">recombinant human interferon beta-1b</a> and <a class="drug drug_general" data-topicid="8565" href="/z/d/drug information/8565.html" rel="external">recombinant human interferon beta-1a</a>) and <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a>. These DMTs may be preferred by patients who place the highest value on safety and are willing to accept lower effectiveness  (<a class="graphic graphic_algorithm graphicRef102519" href="/z/d/graphic/102519.html" rel="external">algorithm 1</a>). The dose, administration, and monitoring of these agents are described above. (See <a class="local">'Interferons'</a> above and <a class="local">'Glatiramer acetate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other immune modulating agents</strong> – Before the approval of injection therapies (interferons and <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a>), and based on limited evidence, several immunosuppressive agents were used to treat MS, including <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, glucocorticoids, intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a>, and <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a>. However, these agents are less often used for MS now that DMTs with proven efficacy are available. (See <a class="local">'Other immune modulating agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stem cell transplantation</strong> – Hematopoietic and mesenchymal stem cell therapy are promising investigational therapies for MS, but long-term data from randomized controlled trials are needed to assess the efficacy and safety of these therapies. (See <a class="local">'Stem cell transplantation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">La Mantia L, Di Pietrantonj C, Rovaris M, et al. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2014; :CD009333.</a></li><li><a class="nounderline abstract_t">Kasper LH, Reder AT. Immunomodulatory activity of interferon-beta. Ann Clin Transl Neurol 2014; 1:622.</a></li><li><a class="nounderline abstract_t">Goldschmidt CH, Hua LH. Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy. Degener Neurol Neuromuscul Dis 2020; 10:29.</a></li><li><a class="nounderline abstract_t">Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 2011; 25:491.</a></li><li class="breakAll">Plegridy (peginterferon beta-1a) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125499s028lbl.pdf (Accessed on October 29, 2023).</li><li class="breakAll">Betaseron (interferon beta-1b) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103471s5202lbl.pdf (Accessed on October 29, 2023).</li><li class="breakAll">Avonex (interferon beta-1a) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103628s5269lbl.pdf (Accessed on October 29, 2023).</li><li class="breakAll">Rebif (interferon beta-1a) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103780s5214lbl.pdf (Accessed on October 29, 2023).</li><li><a class="nounderline abstract_t">Río J, Nos C, Bonaventura I, et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology 2004; 63:525.</a></li><li><a class="nounderline abstract_t">Patten SB, Francis G, Metz LM, et al. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005; 11:175.</a></li><li><a class="nounderline abstract_t">Alba Palé L, León Caballero J, Samsó Buxareu B, et al. Systematic review of depression in patients with multiple sclerosis and its relationship to interferonβ treatment. Mult Scler Relat Disord 2017; 17:138.</a></li><li><a class="nounderline abstract_t">Solaro C, Gamberini G, Masuccio FG. Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment. CNS Drugs 2018; 32:117.</a></li><li><a class="nounderline abstract_t">Nikfar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Clin Ther 2010; 32:1871.</a></li><li><a class="nounderline abstract_t">Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology 2004; 62:628.</a></li><li><a class="nounderline abstract_t">Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf 2003; 26:815.</a></li><li><a class="nounderline abstract_t">Demerouti E, Karyofyllis P, Athanassopoulos G, et al. Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review. Mult Scler Relat Disord 2019; 28:273.</a></li><li><a class="nounderline abstract_t">Raza F, Kozitza C, Chybowski A, et al. Interferon-β-Induced Pulmonary Arterial Hypertension: Approach to Diagnosis and Clinical Monitoring. JACC Case Rep 2021; 3:1038.</a></li><li><a class="nounderline abstract_t">Hunt D, Kavanagh D, Drummond I, et al. Thrombotic microangiopathy associated with interferon beta. N Engl J Med 2014; 370:1270.</a></li><li><a class="nounderline abstract_t">Olea T, Díaz-Mancebo R, Picazo ML, et al. Thrombotic microangiopathy associated with use of interferon-beta. Int J Nephrol Renovasc Dis 2012; 5:97.</a></li><li><a class="nounderline abstract_t">Kavanagh D, McGlasson S, Jury A, et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood 2016; 128:2824.</a></li><li><a class="nounderline abstract_t">Ekstein D, Linetsky E, Abramsky O, Karussis D. Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis. Neurology 2005; 65:456.</a></li><li><a class="nounderline abstract_t">Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362:1184.</a></li><li><a class="nounderline abstract_t">Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004; 62:2031.</a></li><li><a class="nounderline abstract_t">Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65:40.</a></li><li><a class="nounderline abstract_t">Francis GS, Rice GP, Alsop JC, PRISMS Study Group. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65:48.</a></li><li><a class="nounderline abstract_t">Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68:977.</a></li><li><a class="nounderline abstract_t">Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003; 60:634.</a></li><li><a class="nounderline abstract_t">Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65:33.</a></li><li><a class="nounderline abstract_t">Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352:1498.</a></li><li><a class="nounderline abstract_t">Giovannoni G, Goodman A. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology 2005; 65:6.</a></li><li><a class="nounderline abstract_t">Rudick RA, Ransohoff RM. Biomarkers for interferon response in MS: are we there yet? Neurology 2008; 70:1069.</a></li><li><a class="nounderline abstract_t">Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9:740.</a></li><li><a class="nounderline abstract_t">Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43:655.</a></li><li><a class="nounderline abstract_t">Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995; 45:1277.</a></li><li><a class="nounderline abstract_t">Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012; 78:1315.</a></li><li><a class="nounderline abstract_t">Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39:285.</a></li><li><a class="nounderline abstract_t">Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59:1507.</a></li><li><a class="nounderline abstract_t">Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002; 59:1496.</a></li><li><a class="nounderline abstract_t">Lublin FD. When marketing and science intersect: do patients with MS benefit? Neurology 2002; 59:1480.</a></li><li><a class="nounderline abstract_t">Kieburtz K, McDermott M. Needed in MS: evidence, not EVIDENCE. Neurology 2002; 59:1482.</a></li><li><a class="nounderline abstract_t">Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol 2005; 62:785.</a></li><li><a class="nounderline abstract_t">Kieseier BC, Calabresi PA. PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis. CNS Drugs 2012; 26:205.</a></li><li><a class="nounderline abstract_t">Oh J, Calabresi PA. Emerging injectable therapies for multiple sclerosis. Lancet Neurol 2013; 12:1115.</a></li><li><a class="nounderline abstract_t">Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014; 13:657.</a></li><li><a class="nounderline abstract_t">Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359:1453.</a></li><li><a class="nounderline abstract_t">PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56:1628.</a></li><li><a class="nounderline abstract_t">Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67:944.</a></li><li><a class="nounderline abstract_t">Rudick RA, Cutter G. Interferon-beta for multiple sclerosis: Long-term benefits? Ann Neurol 2007; 61:283.</a></li><li><a class="nounderline abstract_t">Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61:300.</a></li><li><a class="nounderline abstract_t">Renoux C, Suissa S. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis. Ann Neurol 2008; 64:109.</a></li><li><a class="nounderline abstract_t">Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308:247.</a></li><li><a class="nounderline abstract_t">Drulovic J, Kostic J, Mesaros S, et al. Interferon-beta and disability progression in relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg 2013; 115 Suppl 1:S65.</a></li><li><a class="nounderline abstract_t">Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A 2004; 101 Suppl 2:14593.</a></li><li class="breakAll">Copaxone (glatiramer acetate) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020622s115lbl.pdf (Accessed on October 29, 2023).</li><li><a class="nounderline abstract_t">Bains SN, Hsieh FH, Rensel MR, et al. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis. Ann Allergy Asthma Immunol 2010; 104:321.</a></li><li><a class="nounderline abstract_t">Subramaniam K, Pavli P, Llewellyn H, Chitturi S. Glatiramer acetate induced hepatotoxicity. Curr Drug Saf 2012; 7:186.</a></li><li><a class="nounderline abstract_t">Makhani N, Ngan BY, Kamath BM, Yeh EA. Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS. Neurology 2013; 81:850.</a></li><li><a class="nounderline abstract_t">Real M, Barnhill MS, Higley C, et al. Drug-Induced Liver Injury: Highlights of the Recent Literature. Drug Saf 2019; 42:365.</a></li><li><a class="nounderline abstract_t">Salama HH, Hong J, Zang YC, et al. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 2003; 126:2638.</a></li><li><a class="nounderline abstract_t">La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2010; :CD004678.</a></li><li><a class="nounderline abstract_t">Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:1268.</a></li><li><a class="nounderline abstract_t">Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50:701.</a></li><li><a class="nounderline abstract_t">Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013; 73:705.</a></li><li><a class="nounderline abstract_t">McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA 2021; 325:765.</a></li><li><a class="nounderline abstract_t">Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 1988; 2:179.</a></li><li><a class="nounderline abstract_t">Goodkin DE, Bailly RC, Teetzen ML, et al. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991; 41:20.</a></li><li><a class="nounderline abstract_t">Milanese C, La Mantia L, Salmaggi A, Eoli M. A double blind study on azathioprine efficacy in multiple sclerosis: final report. J Neurol 1993; 240:295.</a></li><li><a class="nounderline abstract_t">Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 2007; :CD003982.</a></li><li><a class="nounderline abstract_t">Massacesi L, Parigi A, Barilaro A, et al. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 2005; 62:1843.</a></li><li><a class="nounderline abstract_t">Killian JM, Bressler RB, Armstrong RM, Huston DP. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol 1988; 45:27.</a></li><li><a class="nounderline abstract_t">Gladstone DE, Zamkoff KW, Krupp L, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 2006; 63:1388.</a></li><li><a class="nounderline abstract_t">Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008; 65:1044.</a></li><li><a class="nounderline abstract_t">Ravnborg M, Sørensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9:672.</a></li><li><a class="nounderline abstract_t">Cohen JA, Imrey PB, Calabresi PA, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009; 72:535.</a></li><li><a class="nounderline abstract_t">Sorensen PS, Mellgren SI, Svenningsson A, et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009; 8:519.</a></li><li><a class="nounderline abstract_t">Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349:589.</a></li><li><a class="nounderline abstract_t">Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50:398.</a></li><li><a class="nounderline abstract_t">Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50:1273.</a></li><li><a class="nounderline abstract_t">Lewańska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 2002; 9:565.</a></li><li><a class="nounderline abstract_t">Noseworthy JH, O'Brien PC, Weinshenker BG, et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000; 55:1135.</a></li><li><a class="nounderline abstract_t">Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58:169.</a></li><li><a class="nounderline abstract_t">Fazekas F, Lublin FD, Li D, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008; 71:265.</a></li><li><a class="nounderline abstract_t">Cocco E, Marrosu MG. The current role of mitoxantrone in the treatment of multiple sclerosis. Expert Rev Neurother 2014; 14:607.</a></li><li><a class="nounderline abstract_t">Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90:777.</a></li><li><a class="nounderline abstract_t">Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61:1332.</a></li><li><a class="nounderline abstract_t">Marriott JJ, Miyasaki JM, Gronseth G, et al. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1463.</a></li><li><a class="nounderline abstract_t">Boster A, Edan G, Frohman E, et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol 2008; 7:173.</a></li><li><a class="nounderline abstract_t">Atkins HL, Freedman MS. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics 2013; 10:68.</a></li><li><a class="nounderline abstract_t">Burt RK, Balabanov R, Burman J, et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA 2019; 321:165.</a></li><li><a class="nounderline abstract_t">Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol 2015; 72:159.</a></li><li><a class="nounderline abstract_t">Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology 2017; 88:842.</a></li><li><a class="nounderline abstract_t">Atkins HL, Bowman M, Allan D, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 2016; 388:576.</a></li><li><a class="nounderline abstract_t">Collins F, Kazmi M, Muraro PA. Progress and prospects for the use and the understanding of the mode of action of autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis. Expert Rev Clin Immunol 2017; 13:611.</a></li><li><a class="nounderline abstract_t">Cohen JA, Baldassari LE, Atkins HL, et al. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2019; 25:845.</a></li><li><a class="nounderline abstract_t">Muraro PA, Pasquini M, Atkins HL, et al. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol 2017; 74:459.</a></li><li><a class="nounderline abstract_t">Boffa G, Massacesi L, Inglese M, et al. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology 2021; 96:e1215.</a></li><li><a class="nounderline abstract_t">Nicholas RS, Rhone EE, Mariottini A, et al. Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series. Neurology 2021; 97:e890.</a></li><li><a class="nounderline abstract_t">Boffa G, Signori A, Massacesi L, et al. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis. Neurology 2023; 100:e1109.</a></li><li><a class="nounderline abstract_t">Sharrack B, Petrie J, Coles A, Snowden JA. Is stem cell transplantation safe and effective in multiple sclerosis? BMJ 2022; 377:e061514.</a></li><li><a class="nounderline abstract_t">Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008; 7:626.</a></li><li><a class="nounderline abstract_t">Fassas A, Kimiskidis VK, Sakellari I, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 2011; 76:1066.</a></li><li><a class="nounderline abstract_t">Mancardi GL, Sormani MP, Di Gioia M, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 2012; 18:835.</a></li><li><a class="nounderline abstract_t">Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant 2010; 16:S48.</a></li><li><a class="nounderline abstract_t">Reston JT, Uhl S, Treadwell JR, et al. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler 2011; 17:204.</a></li><li><a class="nounderline abstract_t">Popat U, Krance R. Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br J Haematol 2004; 126:637.</a></li><li><a class="nounderline abstract_t">Hough RE, Snowden JA, Wulffraat NM. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol 2005; 128:432.</a></li><li><a class="nounderline abstract_t">Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011; 10:649.</a></li><li><a class="nounderline abstract_t">Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11:150.</a></li><li><a class="nounderline abstract_t">Rice CM, Kemp K, Wilkins A, Scolding NJ. Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet 2013; 382:1204.</a></li><li><a class="nounderline abstract_t">Petrou P, Kassis I, Levin N, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain 2020; 143:3574.</a></li><li><a class="nounderline abstract_t">Uccelli A, Laroni A, Ali R, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol 2021; 20:917.</a></li><li><a class="nounderline abstract_t">Yamout BI, Zakaria M, Inshasi J, et al. MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. Mult Scler Relat Disord 2021; 56:103225.</a></li><li class="breakAll">COVID-19 Vaccine Guidance for People Living with MS. National Multiple Sclerosis Society. Available at: https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance (Accessed on January 14, 2022).</li><li><a class="nounderline abstract_t">Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 Vaccine Response in People with Multiple Sclerosis. Ann Neurol 2022; 91:89.</a></li><li><a class="nounderline abstract_t">Louapre C, Ibrahim M, Maillart E, et al. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 2022; 93:24.</a></li><li><a class="nounderline abstract_t">Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 2021; 27:1990.</a></li><li class="breakAll">ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the COVID19 pandemic. Available at: https://www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/21.10.26_ABN_Guidance_on_DMTs_for_MS_and_COVID-19.pdf (Accessed on January 19, 2022).</li><li><a class="nounderline abstract_t">Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol 2021; 89:780.</a></li><li><a class="nounderline abstract_t">Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol 2020; 77:1079.</a></li><li><a class="nounderline abstract_t">Hughes R, Whitley L, Fitovski K, et al. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord 2021; 49:102725.</a></li><li><a class="nounderline abstract_t">Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology 2021; 97:e1870.</a></li><li><a class="nounderline abstract_t">Hada M, Mosholder AD, Leishear K, Perez-Vilar S. Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Neurol Sci 2022; 43:1557.</a></li><li><a class="nounderline abstract_t">Salter A, Fox RJ, Newsome SD, et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol 2021; 78:699.</a></li><li><a class="nounderline abstract_t">Giovannoni G, Hawkes C, Lechner-Scott J, et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord 2020; 39:102073.</a></li><li class="breakAll">National Multiple Sclerosis Society. MS treatment guidelines during coronavirus. Available at: https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/ms-treatment-guidelines-during-coronavirus (Accessed on January 19, 2022).</li></ol></div><div id="topicVersionRevision">Topic 129091 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25062935" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25356432" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Immunomodulatory activity of interferon-beta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32617031" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Re-Evaluating the Use of IFN-βand Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21649449" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The mechanism of action of interferon-βin relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21649449" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The mechanism of action of interferon-βin relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21649449" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The mechanism of action of interferon-βin relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21649449" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The mechanism of action of interferon-βin relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21649449" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The mechanism of action of interferon-βin relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304586" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15794391" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29055445" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Systematic review of depression in patients with multiple sclerosis and its relationship to interferonβtreatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29417493" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21095482" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A meta-analysis of the efficacy and tolerability of interferon-βin multiple sclerosis, overall and by drug and disease type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981183" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Liver injury associated with the beta-interferons for MS: a comparison between the three products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12908850" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30639829" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34317680" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interferon-β-Induced Pulmonary Arterial Hypertension: Approach to Diagnosis and Clinical Monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24670186" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Thrombotic microangiopathy associated with interferon beta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22815645" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Thrombotic microangiopathy associated with use of interferon-beta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27663672" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087915" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568740" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184610" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009883" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009884" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17389300" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601105" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888603" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820297" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009876" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18362268" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Biomarkers for interferon response in MS: are we there yet?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610349" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8469318" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7617182" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22496198" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602746" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451189" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451188" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451185" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : When marketing and science intersect: do patients with MS benefit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451186" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Needed in MS: evidence, not EVIDENCE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883267" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22201341" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24090587" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Emerging injectable therapies for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24794721" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pegylated interferonβ-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11988242" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11425926" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000959" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17444503" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Interferon-beta for multiple sclerosis: Long-term benefits?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17444502" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : New natural history of interferon-beta-treated relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668635" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22797642" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24321159" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Interferon-beta and disability progression in relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15371592" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15371592" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20408342" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22873505" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Glatiramer acetate induced hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23884038" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30343418" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Drug-Induced Liver Injury: Highlights of the Recent Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12937077" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20464733" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Glatiramer acetate for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7617181" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521260" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23686821" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33620411" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Diagnosis and Treatment of Multiple Sclerosis: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2899660" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985289" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The efficacy of azathioprine in relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8326334" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A double blind study on azathioprine efficacy in multiple sclerosis: final report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943809" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Azathioprine for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344342" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276298" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908728" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541787" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20542736" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204263" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19409854" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9057729" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484361" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9595974" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12453070" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11071491" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : IV immunoglobulin does not reverse established weakness in MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11805241" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645164" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24834466" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The current role of mitoxantrone in the treatment of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29686116" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638950" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439849" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18207115" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23192675" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30644983" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25546364" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28148635" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27291994" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28277827" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Progress and prospects for the use and the understanding of the mode of action of autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30794930" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241268" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33472915" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34253634" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36543569" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35680142" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Is stem cell transplantation safe and effective in multiple sclerosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565456" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Autologous haematopoietic stem-cell transplantation in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422458" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Long-term results of stem cell transplantation for MS: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22127896" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19895895" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20921236" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327514" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15686452" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21683930" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22236384" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24095194" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33253391" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34687636" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34479111" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34479111" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34687063" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : COVID-19 Vaccine Response in People with Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34341142" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34522051" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34522051" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33480077" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32589189" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33482590" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : COVID-19 in ocrelizumab-treated people with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34610987" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35006442" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33739362" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32334820" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : The COVID-19 pandemic and the use of MS disease-modifying therapies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
